

Review

Role of fibroblast growth factors in organ regeneration and repair

Elie El Agha^a, Djuro Kosanovic^a, Ralph T. Schermuly^a, Saverio Bellusci^{a,b,*}^a Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Excellence Cluster Cardio-Pulmonary System (ECCPS), Justus-Liebig-University, Giessen, Hessen, Germany^b Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia

ARTICLE INFO

Article history:

Received 5 May 2015

Accepted 8 October 2015

Available online 13 October 2015

Keywords:

Fibroblast growth factors

Organogenesis

Homeostatic balance

Regeneration

Repair

ABSTRACT

In its broad sense, regeneration refers to the renewal of lost cells, tissues or organs as part of the normal life cycle (skin, hair, endometrium *etc.*) or as part of an adaptive mechanism that organisms have developed throughout evolution. For example, worms, starfish and amphibians have developed remarkable regenerative capabilities allowing them to voluntarily shed body parts, in a process called autotomy, only to replace the lost parts afterwards. The bizarre myth of the fireproof homicidal salamander that can survive fire and poison apple trees has persisted until the 20th century. Salamanders possess one of the most robust regenerative machineries in vertebrates and attempting to draw lessons from limb regeneration in these animals and extrapolate the knowledge to mammals is a never-ending endeavor.

Fibroblast growth factors are potent morphogens and mitogens that are highly conserved among the animal kingdom. These growth factors play key roles in organogenesis during embryonic development as well as homeostatic balance during postnatal life. In this review, we provide a summary about the current knowledge regarding the involvement of fibroblast growth factor signaling in organ regeneration and repair. We also shed light on the use of these growth factors in previous and current clinical trials in a wide array of human diseases.

© 2015 Elsevier Ltd. All rights reserved.

Contents

1. Introduction.....	76
1.1. Historical background.....	76
1.2. Modes of action.....	77
2. FGFs in tissue regeneration and repair.....	77
2.1. Heart.....	77
2.2. Lung.....	78
2.3. Liver.....	79
2.4. Skeletal muscle.....	79
2.5. Adipose tissue.....	79
3. Clinical applications of recombinant FGFs in organ regeneration and repair.....	79
4. Conclusions.....	80
Acknowledgements.....	80
References.....	80

1. Introduction

1.1. Historical background

Fibroblast growth factors (FGFs) constitute a family of evolutionary conserved polypeptides that are involved in diverse morphogenic and organogenic programs during embryonic development as well as homeostatic balance during postnatal life.

* Corresponding author at: Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Excellence Cluster Cardio-Pulmonary System (ECCPS), Justus-Liebig-University, Giessen, Hessen, Germany.

E-mail address: Saverio.Bellusci@innere.med.uni-giessen.de (S. Bellusci).

The FGF story dates back to the mid-70s when Hugo A. Armelin observed that pituitary extracts had a proliferative effect on NIH3T3 fibroblasts growing *in vitro* [1]. Reasonably, the putative mitogen was dubbed FGF, although it was later discovered that some FGF subfamilies act as “epithelial growth factors” that target the epithelial lining of many organs. Soon after Armelin’s discovery, basic FGF (bFGF or FGF2) was purified from bovine pituitary gland and acidic FGF (aFGF or FGF1) was purified from bovine brain [2–4]. To date, the mammalian FGF gene family, which maps to multiple chromosomes, has been shown to consist of 22 members (FGF1–23). FGF15 has not been identified in humans whereas Fgf19 has not been identified in mice or rats.

Rapid scientific and technological breakthroughs in mouse mutagenesis and the emergence of transgenic mouse technology in the 80s (reviewed in [5,6]) paved the way for the generation of knockout (KO) mice for most known Fgfs (at that time) during the late 90s, allowing to study the functions of various FGF subfamilies (reviewed in [7]). The only FGF that still lacks a reported KO phenotype is FGF11.

1.2. Modes of action

According to their mode of action, FGFs can be broadly classified into paracrine, endocrine and intracrine FGFs. Paracrine FGFs (FGF1, 4, 7, 9 and 8 subfamilies) bind with high affinities to heparin/heparan sulphate (H/HS), which serve as cofactors for their interaction with FGF receptors (FGFRs). FGFR1–4 are receptor tyrosine kinases that activate downstream signaling cascades including RAS/RAF/MAPK, PI3K/AKT, PLC γ and STAT. Paracrine FGFs are involved in the development of multiple organs such as the heart, lung, brain, muscle, kidney, hair, ear and limb (reviewed in [8]).

Endocrine FGFs (FGF15/19, 21 and 23) are vertebrate-specific hormone-like FGFs that are involved in multiple metabolic pathways such as glucose, lipid and phosphate metabolism. They have low affinities to FGFRs and H/HS, which enables them to function in a hormone-like fashion. Endocrine FGFs require α/β -Klotho as a coreceptor to mediate metabolic effects [9–14].

Unlike other FGFs, intracrine FGFs (FGF11–14) do not signal through FGFRs. Rather, they are retained inside the cells where they interact with the cytoplasmic domain of voltage-gated sodium channels and subsequently control neuronal excitability [15,16].

As this review aims to highlight the role of FGF signaling in organ regeneration and repair, we will try to provide a comprehensive overview about the history and current knowledge regarding this specific aspect. For a more in-depth description and phylogenetic analysis of FGFs and their receptors, and their involvement in normal development, homeostatic maintenance and disease, we refer the readers to excellent reviews previously published [7,8,17–23].

2. FGFs in tissue regeneration and repair

Following the discovery of FGF1/2 in bovine brain and pituitary gland, extracts from these organs and later recombinant proteins were used to stimulate wound healing in skin [24,25], cornea [26,27], cartilage [28], peritoneum [29], peripheral nerve [30], vasculature [31], brain [32,33], eardrum [34], striated muscle [35], duodenal ulcers [36], salivary glands [37], tibia [38] and sternum [39], just to name a few. Most of these studies were conducted on mammalian species such as rats, mice, rabbits and dogs.

FGF7 (or keratinocyte growth factor; KGF) was first purified in 1989 [40] and its skin-wound healing capability was later demonstrated [41,42]. Interestingly, expression of a dominant negative form of Fgf2, the cognate receptor of FGF7, resulted in blockage of branching morphogenesis in the embryonic mouse lung

[43], a phenotype that would later be shown to be characteristic of FGF10/FGFR2b blockage. Moreover, Fgf7 KO mice displayed impaired hair development but a normal wound-healing capacity, suggesting the presence of redundancy between FGF7 and another unknown factor [44]. Around the same time, FGF10 (KGF2) was discovered by homology PCR [45,46] and its roles in chick limb bud outgrowth [47] and murine lung endoderm branching [48] were reported. Whereas Fgf7 KO mutation in mice showed to be viable, Fgf10 KO mice died shortly after birth due to multi-organ agenesis [49,50].

As mentioned previously, KO mice for almost all FGF members have already been generated and characterized. Some of these KOs have congenital/built-in defects related to regeneration and repair after injury such as Fgf2 (impaired heart regeneration) and Fgf6 (impaired muscle regeneration). On the other hand, many Fgf KOs are lethal (embryonic or postnatal) due to the critical roles of FGF ligands in blastocyst formation (Fgf4), gastrulation (Fgf8), organogenesis (Fgf9, 10, 18) or metabolism (Fgf15/19, 21, 23) (reviewed in [8]). Thus, their therapeutic and regenerative potential has been studied in the context of injury models accompanied by recombinant FGF treatment or genetic intervention such as inducible overexpression of ligands, inducible conditional KO of ligands or receptors and inducible overexpression of dominant negative decoy receptors. Using the soluble FGFR2b decoy receptor to inhibit FGFR2b ligand activity, our group has already shown that FGFR2b signaling is critical for the maintenance of the apical ectodermal ridge (AER) during limb organogenesis [51], controls the regenerative capacity of the adult mouse incisors [52] and is important for postnatal mammary gland development [53]. We also showed, using Fgf10-lacZ reporter mice, that Fgf10 expression is induced in the ileal crypt epithelium after massive small bowel resection, suggesting a role for FGF10 in gut adaptation [54]. Our group was one of the few groups to perform lineage-tracing studies on Fgf-expressing cells, in particular FGF10 [55]. We showed that Fgf10-expressing cells give rise to multiple mesenchymal lineages during murine lung development [56]. We also showed that Fgf10-expressing tanycytes add new neurons to the appetite and energy balance-regulating centers in the adult mouse hypothalamus [57,58].

In the following sections, we will summarize the main findings from studies that investigated the role of FGFs in organ regeneration and repair, with emphasis on the heart, lung, liver, skeletal muscle and adipose tissue. An FGF homunculus that shows the sites where FGFs have shown to contribute to organ repair and regeneration is depicted in Fig. 1.

2.1. Heart

Contrary to organs and tissues like liver, pancreas, intestine, skin, lung, brain and blood, the mammalian heart lacks any robust regenerative capacity. Whereas cardiomyocyte proliferation in the second heart field is a robust event during early organogenesis, this event is absent during adulthood in mammals, thus hindering heart regeneration and repair after myocardial infarction. Stem cell research during the past 15 years has enabled the isolation of embryonic and postnatal cardiomyocyte progenitor cells, established protocols to differentiate them into mature (beating) cardiomyocytes *in vitro* and subsequently inject these cells into the injured mouse heart where they repair the scars caused by myocardial infarction (reviewed in [59]). These achievements have tempted the scientific and clinical communities to believe that the heart might yet possess a regenerative potential that can be stimulated and manipulated.

Many FGFs have been shown to control cardiomyocyte proliferation during embryogenesis including FGF9, 16 and 20. KO pups for these FGFs suffer from congenital heart defects due to impaired




Fig. 1. The FGF homunculus. The main FGFs that are involved in organ regeneration and repair are shown.

cardiomyocyte proliferation [60,61]. Another key player in this context is FGF10, which is expressed in the second heart field during early heart development. *Fgf10*-expressing cells serve as progenitors for the outflow tract and right ventricle [62]. It was shown that FGF10, secreted by the myocardium, acts on the epicardium expressing FGFR1/2b to induce an epicardial-to-myocardial transition. Epicardial-derived cells would then give rise to cardiomyocytes [63]. Additionally, *Fgf10* KOs suffer from misplacement of the heart inside the thoracic cavity and right ventricular hypoplasia due to decreased cardiomyocyte proliferation [64]. FGF10 has also been shown to induce cardiomyocyte cell cycle re-entry in the fetal heart, a phenomenon mediated by FOXO3/p27^{kip1} [65]. Whereas *Fgf10* overexpression in adult mice promotes cell-cycle re-entry of cardiomyocytes but not cardiac fibroblasts [65], it does not seem to offer any benefit in a mouse model of neonatal heart injury, although it leads to epicardial expansion [66].

FGF1 has also been shown to induce cardiomyocyte cell-cycle re-entry [67]. In the latter study, the authors showed that FGF1/p38 MAPK inhibitor treatment induces cardiomyocyte proliferation, reduces heart scarring and rescues heart function. This work was followed up by a study demonstrating that the interaction between FGF-inducible 14-kDa protein (Fn14) [68] and FGFR1 mediates the proliferative effect conferred by FGF1 on cardiomyocytes [69].

Another member of the FGF family that has been studied in this context is FGF2. When cardiac progenitors were isolated from wild

type and *Fgf2* KO mice and infused into WT or *Fgf2* KO adult mice, both cell populations were capable of homing to the cardiac infarct. However, it was only in the presence of FGF2 that progenitors were able to differentiate into mature cardiomyocytes *in situ* [70].

2.2. Lung

Although the adult mouse lung generally has a low cell turnover rate, this organ has proven to possess a decent regenerative capacity after injury. In the adult C57BL6 mouse lung, the most significantly expressed FGFs are FGF1, 2, 7, 9, 10, 18 and 23 [71]. Some of these ligands have already been investigated during lung injury and repair. FGF1, which binds with high affinity to all known FGFRs, has shown to be upregulated in fibrotic lungs and could be detected on alveolar epithelial cells (AECs) and macrophages [72]. FGF1 has also been shown to inhibit α -smooth muscle actin (α Sma) expression and induce apoptosis in normal human lung fibroblasts [73]. The same group also showed that FGF1 treatment inhibits TGF β 1-induced epithelial-to-mesenchymal transition (EMT) through effects on MAPK/ERK pathway, leading to ERK1 phosphorylation and SMAD2 dephosphorylation *in vitro* [74]; thus, FGF1 is generally regarded as an anti-fibrotic agent in idiopathic pulmonary fibrosis (IPF).

FGF2, the other member of the FGF1 subfamily, is expressed by epithelial, inflammatory and endothelial cells, and binds with high affinity to the mesenchymal “c” splice isoform of FGFRs (and with lower affinity to epithelial FGFRs). FGF2 has been shown to mediate TGF β 1-induced myofibroblast differentiation and proliferation [75]; thus it is mostly regarded as a pro-fibrotic agent. In fact, inhibition of FGFR2c signaling has been shown to inhibit α Sma expression and thus attenuate lung fibrosis in mice [76]. Interestingly, *Fgf2* KO mice do not seem to be protected against bleomycin-induced pulmonary fibrosis; rather, FGF2 seems to be critical for epithelial recovery after Naphthalene injury [77]. Both, FGF1 and 2, were shown to induce proliferation of rat alveolar type 2 cells *in vitro* [78] and are therefore believed to be beneficial for epithelial stem cell protection and maintenance in the lung.

FGF1 and 2 have also been studied in the context of pulmonary hypertension (PH) and they seem to mediate hypoxia-induced endothelin receptor A upregulation in pulmonary artery smooth muscle cells [79]. FGF2 levels are elevated in urine and plasma of patients with pulmonary arterial hypertension (PAH) [80]. In the lung, endothelial-derived FGF2 signals in an autocrine fashion and alters endothelial cell phenotype, thus contributing to the progression of PH in humans and rodents [81,82]. It was also demonstrated that FGF2, along with interleukin (IL)-6, mediates increased pericyte coverage and that the latter cells serve as a source of smooth muscle-like cells in PH [83]. Furthermore, deficiency in *Apelin*, a gene encoding a peptide that is highly expressed by endothelial cells and important for homeostatic maintenance in these cells, controls the expression of *miR424* and *miR503*, an event that in turn targets the expression of *FGF2* and *FGFR1* in pulmonary artery endothelial cells (PAECs). Impaired Apelin signaling in multiple PAEC cell lines, derived from idiopathic PAH (IPAH) and familial PAH (FPAH), leads to downregulation of *miR424* and *miR503* that in turn lead to augmented FGF2/FGFR1 signaling [84].

FGF7 and 10 have been shown to be critical for lung regeneration and repair in many models of lung injury. Application of recombinant FGF7 confers beneficial effects in the hyperoxia model of bronchopulmonary dysplasia (BPD) in newborn rats [85] as well as the elastase model of lung emphysema in adult mice [86,87]. FGF10 is downregulated in lungs from BPD patients [88] and the therapeutic potential of FGF10 in the hyperoxia model of BPD in mice is currently being investigated in our group. Additionally, our group has previously demonstrated that *Fgf10* overexpression is protective and curative against bleomycin-induced pulmonary

fibrosis in mice [89]. Interestingly, *FGF10* haploinsufficiency has been shown to be associated with chronic obstructive pulmonary disease (COPD) [90] and it will be tempting to speculate that FGF10 might have a therapeutic effect in the cigarette-smoke exposure model of lung emphysema in mice.

Apart from its therapeutic effects in diseases related to pulmonary parenchymal remodeling, FGF10 has also been shown to contribute to epithelial regeneration. Following Naphthalene injury that depletes the lung epithelium from secretory (Clara) cells, *Fgf10* expression is induced in the underlying airway smooth muscle layer, and FGF10 acts on surviving Clara cells at the bronchoalveolar duct junction and near neuroepithelial bodies to activate Notch signaling and induce transient EMT. These cells then regenerate the nude epithelium [91]. Lastly, *Fgf10* is expressed by resident mesenchymal stem cells that represent a main component of the niche that supports the growth of lung epithelial stem cells, a feature that is inhibited by TGF β 1 [56,92–94].

2.3. Liver

The liver is known for its robust regenerative capacity. Hepatic stellate cells (HSC; previously called hepatic lipocytes) are lipid-containing pericyte-like cells that are involved in the repair process following liver injury [95]. These cells are believed to be the main source of collagen in liver cirrhosis [96,97]. *Fgf7* is upregulated in activated HSC in the fibrotic liver [98]. In mice, liver regeneration appears to be highly dependent on FGFR2b signaling since attenuating FGFR2b signaling, via the overexpression of a soluble dominant negative form of *Fgfr2b*, greatly compromises the repair process after hepatectomy [99]. HSC-derived FGF7 improves liver regeneration and promotes hepatocyte proliferation via signaling through FGFR2b [100]. FGF7 has also been shown to be expressed by liver progenitor cells (LPC) and its signaling is critical for LPC-mediated repair in severely injured livers where hepatocyte proliferation is significantly impaired [101]. Although FGF10 is critical for liver growth during embryogenesis [102], it remains to be established whether it is also involved, like FGF7, in liver regeneration during adulthood.

FGF9 is upregulated in HSC, and acts on hepatocytes to induce proliferation during toxic liver injury [103]. More recently, it was shown that the FGF15/FGFR4/STAT3 signaling pathway also plays an important role in promoting hepatocyte proliferation in compensatory liver growth [104–106].

2.4. Skeletal muscle

Satellite cells are considered to be the stem cells in skeletal muscle. Similarly to stem cells in other organs and tissues, satellite cells represent a minority in the muscle tissue. Their proliferation, differentiation and fusion into myofibers during muscle growth have been thoroughly studied [107]. In this context, FGF2 has been shown to induce proliferation of skeletal muscle satellite cells *in vitro* [108,109]. The expression patterns of FGF1 and 2 have been described in the degenerating and regenerating areas of dystrophic striated muscle in mice, suggesting a role in muscle regeneration [35,110]. Indeed, it was shown that injection of recombinant FGF2 or *FGF2*-overexpressing myoblasts improves muscle regeneration in rodents [111,112]. An interesting phenomenon was reported when investigating the status of satellite cells in aged mice. It was shown that muscle fibers, constituting the stem cell niche, express *Fgf2* under homeostatic conditions. FGF2 signals to satellite cells to break their quiescence, but by virtue of expressing the FGF signaling inhibitor *Sprouty1* (or *Spry1*), satellite cells are able to maintain their quiescent status (p27⁺ *Spry1*⁺). On the other hand, aged muscle fibers significantly upregulate *Fgf2*, forcing satellite cells to break their quiescence, leading to their depletion. Thus, FGF2/FGFR1

signaling blockade might offer a therapeutic opportunity to prevent muscle stem-cell depletion during aging [113].

Another player in muscle regeneration is FGF6. *Fgf6* KO mice display impaired skeletal muscle regeneration due to decreased numbers of *MyoD*- and *Myogenin*-expressing activated satellite cells after injury [114]. Gene delivery of *Fgf6* or *Fgf2* has been shown to enhance skeletal muscle regeneration in animal models of muscle injury [115,116].

2.5. Adipose tissue

White and brown adipose tissues (WAT and BAT) play critical roles in energy preservation and heat generation respectively. WAT is the major fat depot in humans and other mammals, whereas BAT plays a critical role in heat production in the newborn infant and in arousal of hibernating mammals. Four FGF ligands are regarded as adipokines: FGF1, FGF10, FGF16 and FGF21. FGF10 is expressed by both preadipocytes and mature adipocytes and its role in the differentiation of preadipocytes in WAT is well established [117]. *Fgf10* KO newborns display impaired WAT formation [118]. FGF10 confers mitogenic and adipogenic effects on WAT preadipocytes expressing *FGFR2b*. The proliferative effect is mediated by the activation of the MAPK pathway, leading to the induction of *Cyclin D2* expression [119]. At the same time, FGF10-FGFR2b-mediated MAPK activation induces the expression of retinoblastoma protein (*pRb*) that binds CCAAT/enhancer binding protein alpha (C/EBP α) leading to the induction of peroxisome proliferator-activated receptor γ (*Pparg*) expression [120], the master regulator of adipogenesis.

FGF21, first cloned by homology-based PCR from embryonic mouse cDNA [121], has been discovered as a regulator of glucose and lipid metabolism in a screen for novel proteins with antidiabetic potential [122]. FGF21 is a circulating hepatokine that activates the MAPK pathway in adipocytes expressing *Fgfr1c* and β -*Klotho* [123] and regulates PPAR γ activity by preventing sumoylation [124]. FGF21 has also been shown to activate BAT in mice [125].

The involvement of FGF1 in the dynamic WAT remodeling has recently been demonstrated in mice [126]. In response to a high-fat diet, *Fgf1* expression is induced in WAT of wild type mice. *Fgf1* KO mice develop a severe form of diabetes with vascular defects and abnormal adipocyte size within the WAT when fed a high-fat diet, a phenotype that does not properly resolve when the mice return to a normal diet. PPAR γ regulates the expression of *Fgf1* at the transcriptional level by binding to a conserved PPAR response element within the promoter of the *Fgf1* gene [126].

FGF16 is expressed in the rat fetus from embryonic day (E) 17.5 to E19.5, and at lower levels during neonatal life in rat BAT. Recombinant FGF16 has been shown to induce proliferation of primary brown adipocytes isolated from rat embryonic BAT by binding and activating FGFR4. When adult rats are exposed to cold, *Fgf16* shows decreased rather than increased expression in BAT [127].

3. Clinical applications of recombinant FGFs in organ regeneration and repair

The use of recombinant human FGFs, produced in *Escherichia coli* or *Saccharomyces cerevisiae*, to treat human diseases has already been implemented. Recombinant FGF2, mostly used as an angiogenic therapy under the name Trafermin, has shown beneficial effects on patients with pressure sores [128], chronic diabetic neuropathic ulcer of the foot [129], nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcer relapse [130], coronary heart disease [131,132], second-degree burns [133], intermittent claudication [134], sensorineural deafness

[135], chronic sinusitis [136], surgical osteotomy [137], facial depression [138], traumatic ulcers [139], periodontitis [140], atrophied vocal folds [141], myocardial infarction [142], tibial shaft fracture [143], post-operative color uniformity [144], LASIK-induced neurotrophic epitheliopathy [145], peripheral artery disease [146], tympanic membrane perforation [147], photorefractive keratectomy [148] and minor recurrent aphthous stomatitis [149]. FGF2 gene therapy through DVC1-0101 is currently being tested for peripheral arterial disease treatment.

Treatment with recombinant FGF1 led to only modest nerve regeneration in patients with cervical spinal cord injury [150] but facilitated nerve regeneration and motor function recovery in patients with peripheral nerve lesions [151]. Riferminogene pectaplasmid (or NV1FGF), an expression plasmid encoding recombinant FGF1, significantly reduced the risk of major amputation in patients with severe limb ischemia when administered intramuscularly [152]; however, it did not seem to offer significant benefit in another study [153]. FGF1 and NV1FGF are also being tested in the treatment of intermittent claudication, coronary heart disease, diabetic or venous stasis ulcers and peripheral artery occlusive disease. FGF4 gene therapy, through Alferminogene tadenovec (or Ad5FGF4), is being tested for myocardial ischemia in patients with stable angina due to coronary artery disease [154].

Palifermin contains a truncated form of human FGF7 and is used to treat and prevent oral mucositis and dysphagia in hematologic cancer patients undergoing severe chemotherapy and radiation therapy prior to bone marrow transplantation [155]. Palifermin is introduced intravenously and helps to regenerate the mucosal barrier.

Repifermin contains a truncated form of FGF10 and was developed to treat wounds, oral and intestinal mucositis and inflammatory bowel diseases [156]. Repifermin has been shown to accelerate healing in patients with chronic venous ulcers [157] but did not show to be effective in treating active ulcerative colitis in clinical trials [158]. Thus, the development of this drug was ceased in 2004. Yet, attempts to enhance Repifermin's unfolding temperature [159] and ensure sustained release [160] have proven successful in increasing bioavailability and efficacy of Repifermin. This suggests that this drug could be revived and possibly tested in other settings.

4. Conclusions

FGF biology has witnessed an exponential growth since the last quarter of the 20th century. Developmental biologists interested in organogenesis and the associated growth and rearrangement of cells and tissues in space and time have selected 'hot' genes that proved to be indispensable for proper embryonic development, mostly in *Drosophila melanogaster*. FGFs are among the various growth factors that control survival, proliferation, differentiation and migration of stem/progenitor cells in a wide array of species ranging from flies to humans.

The scientific literature is rich with examples on the involvement of developmental signaling pathways in organ regeneration during postnatal life. The FGF signaling pathway is clearly one of the top candidates in this regard. FGF therapy, *via* recombinant proteins or gene delivery, has shown promising results in experimental animals and clinical trials, mostly with cardiovascular disease, skin wounds and burns, bone fractures, gastric ulcers and colitis.

A word of caution has to be stated about the association of aberrant FGF/FGFR signaling with cancer. As mentioned previously, FGFs are potent mitogens and their signaling *via* their cognate FGFRs induces cell survival, proliferation, EMT, invasion and angiogenesis. Thus, aberrant FGF/FGFR signaling can acquire an oncogenic nature and this has been shown in tumors of many

human organs including, but not limited to, the breast and lung (mutations leading to amplification of *FGFR1* and *FGFR2* genes), stomach and endometrium (mutations enhancing kinase activity or altering ligand specificity of *FGFR2*), bladder and prostate (mutations leading to enhanced kinase activity of *FGFR3*), brain (mutations leading to enhanced kinase activity of *FGFR1*) and connective tissue (*FGFR4* mutations) (reviewed in [161,162]). This oncogenic feature represents a challenge when the manipulation of FGF/FGFR signaling to promote tissue repair and regeneration is desired.

Acknowledgements

SB and EEA were supported by grants from the DFG (BE4443/4-1 and BE4443/6-1), LOEWE, ECCPS and UKGM. SB was also supported by the program of competitive growth of Kazan Federal University.

References

- [1] Armelin HA. Pituitary extracts and steroid hormones in the control of 3T3 cell growth. *Proc. Natl. Acad. Sci. U.S.A* 1973;70:2702–6.
- [2] Thomas KA, Rios-Candelore M, Fitzpatrick S. Purification and characterization of acidic fibroblast growth factor from bovine brain. *Proc. Natl. Acad. Sci. U.S.A* 1984;81:357–61.
- [3] Gospodarowicz D, Bialecki H, Greenburg G. Purification of the fibroblast growth factor activity from bovine brain. *J. Biol. Chem* 1978;253:3736–43.
- [4] Gospodarowicz D. Purification of a fibroblast growth factor from bovine pituitary. *J. Biol. Chem* 1975;250:2515–20.
- [5] Palmiter RD, Brinster RL. Germ-line transformation of mice. *Annu. Rev. Genet* 1986;20:465–99, <http://dx.doi.org/10.1146/annurev.genet.20.1.465>.
- [6] Hanahan D, Wagner EF, Palmiter RD. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. *Genes Dev* 2007;21:2258–70, <http://dx.doi.org/10.1101/gad.1583307>.
- [7] Ornitz DM, Itoh N. Protein family review Fibroblast growth factors Gene organization and evolutionary history. *Genome Biol* 2001;2:1–12, <http://dx.doi.org/10.1186/gb-2001-2-3-reviews3005>.
- [8] Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. *J. Biochem* 2011;149:121–30, <http://dx.doi.org/10.1093/jb/mvq121>, mvq121 (pii).
- [9] Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. *J. Bone Min. Res* 2004;19:429–35, <http://dx.doi.org/10.1359/JBMR.0301264>.
- [10] Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. *Nature* 2006;444:770–4, <http://dx.doi.org/10.1038/nature05315>, nature05315 (pii).
- [11] Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. *J Biol Chem* 2007;282:26687–95, <http://dx.doi.org/10.1074/jbc.M704165200>, M704165200 (pii).
- [12] Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. *Endocrinology* 2009;150:4625–33, <http://dx.doi.org/10.1210/en.2009-0119>, en.2009-0119 (pii).
- [13] Adams AC, Coskun T, Rovira ARI, Schneider MA, Raches DW, Micanovic R, et al. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. *PLoS ONE* 2012;7:e38438, <http://dx.doi.org/10.1371/journal.pone.0038438>.
- [14] Kharitonov A, Adams AC. Inventing new medicines: the FGF21 story. *Mol. Metab* 2014;3:221–9, <http://dx.doi.org/10.1016/j.molmet.2013.12.003>.
- [15] Goldfarb M, Schoorlemmer J, Williams A, Diwakar S, Wang Q, Huang X, et al. Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels. *Neuron* 2007;55:449–63, <http://dx.doi.org/10.1016/j.neuron.2007.07.006>, S0896-6273(07)00525-9 (pii).
- [16] Shakkottai VG, Xiao M, Xu L, Wong M, Nerbonne JM, Ornitz DM, et al. FGF14 regulates the intrinsic excitability of cerebellar Purkinje neurons. *Neurobiol. Dis* 2009;33:81–8, doi:S0969-9961(08)00227-1 [pii] [10.1016/j.nbd.2008.09.019](http://dx.doi.org/10.1016/j.nbd.2008.09.019).
- [17] Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. *Trends Genet* 2004;20:563–9, <http://dx.doi.org/10.1016/j.tig.2004.08.007>, S0168-9525(04)00241-0 (pii).
- [18] Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. *Dev. Dyn* 2008;237:18–27, <http://dx.doi.org/10.1002/dvdy.21388>.

- [19] Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. *Nat. Rev. Drug Discov* 2009;8:235–53. <http://dx.doi.org/10.1038/nrd2792>, nrd2792 (pii).
- [20] Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. *Nat. Rev. Mol. Cell Biol* 2013;14:166–80. <http://dx.doi.org/10.1038/nrm3528>.
- [21] Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. *Cold Spring Harb. Perspect. Biol* 2013;5. <http://dx.doi.org/10.1101/cshperspect.a015958>.
- [22] McKeehan WL, Wang F, Kan M. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. *Prog. Nucleic Acid Res. Mol. Biol* 1998;59:135–76.
- [23] Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. *Wiley Interdiscip. Rev. Dev. Biol* 2015. <http://dx.doi.org/10.1002/wdev.176>.
- [24] Buntrock P, Jentsch KD, Heder G. Stimulation of wound healing, using brain extract with fibroblast growth factor (FGF) activity. I. Quantitative and biochemical studies into formation of granulation tissue. *Exp. Pathol* 1982;21:46–53.
- [25] Greenhalgh DG, Sprugel KH, Murray MJ, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. *Am. J. Pathol* 1990;136:1235–46.
- [26] Woost PG, Brightwell J, Eiferman RA, Schultz GS. Effect of growth factors with dexamethasone on healing of rabbit corneal stromal incisions. *Exp. Eye Res* 1985;40:47–60.
- [27] Courtois Y, Grandjean M, Courty J, Barritault D, Pouliquen Y. Effects of the growth factors EDGF I and EDGF II on wound healing of the corneal epithelium in rabbits. *C. R. Seances Soc. Biol. Fil* 1987;181:491–4.
- [28] Cuevas P, Burgos J, Baird A. Basic fibroblast growth factor (FGF) promotes cartilage repair in vivo. *Biochem. Biophys. Res. Commun* 1988;156:611–8. [http://dx.doi.org/10.1016/S0006-291X\(88\)80887-8](http://dx.doi.org/10.1016/S0006-291X(88)80887-8).
- [29] Fukasawa M, Yanagihara DL, Rodgers KE, DiZerega GS. The mitogenic activity of peritoneal tissue repair cells: control by growth factors. *J. Surg. Res* 1989;47:45–51.
- [30] Aebischer P, Salessiotis AN, Winn SR. Basic fibroblast growth factor released from synthetic guidance channels facilitates peripheral nerve regeneration across long nerve gaps. *J. Neurosci. Res* 1989;23:282–9. <http://dx.doi.org/10.1002/jnr.490230306>.
- [31] Reidy MA, Jackson CL. Factors controlling growth of arterial cells following injury. *Toxicol. Pathol* 1990;18:547–53.
- [32] Armstrong R, Friedrich VL, Holmes KV, Dubois-Dalcq M. In vitro analysis of the oligodendrocyte lineage in mice during demyelination and remyelination. *J. Cell Biol* 1990;111:1183–95.
- [33] Gómez-Pinilla F, Lee JW, Cotman CW. Basic FGF in adult rat brain: cellular distribution and response to entorhinal lesion and fimbria-fornix transection. *J. Neurosci* 1992;12:345–55.
- [34] Fina M, Bresnick S, Baird A, Ryan A. Improved healing of tympanic membrane perforations with basic fibroblast growth factor. *Growth Factors* 1991;5:265–72.
- [35] Anderson JE, Liu L, Kardami E. Distinctive patterns of basic fibroblast growth factor (bFGF) distribution in degenerating and regenerating areas of dystrophic (mdx) striated muscles. *Dev. Biol* 1991;147:96–109.
- [36] Folkman J, Szabo S, Stovroff M, McNeil P, Li W, Shing Y. Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. *Ann. Surg* 1991;214:414–25 (discussion 426–427).
- [37] Okazaki Y, Kagami H, Hattori T, Hishida S, Shigetomi T, Ueda M. Acceleration of rat salivary gland tissue repair by basic fibroblast growth factor. *Arch. Oral. Biol* 2000;45:911–9.
- [38] Nakamura T, Hara Y, Tagawa M, Tamura M, Yuge T, Fukuda H, et al. Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. *J. Bone Miner. Res* 1998;13:942–9. <http://dx.doi.org/10.1359/jbmr.1998.13.6.942>.
- [39] Iwakura A, Tabata Y, Tamura N, Doi K, Nishimura K, Nakamura T, et al. Gelatin sheet incorporating basic fibroblast growth factor enhances healing of devascularized sternum in diabetic rats. *Circulation* 2001;104:1325–9.
- [40] Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA. Purification and characterization of a newly identified growth factor specific for epithelial cells. *Proc. Natl. Acad. Sci. U.S.A* 1989;86:802–6.
- [41] Werner S, Peters KG, Longaker MT, Fuller-Pace F, Banda MJ, Williams LT. Large induction of keratinocyte growth factor expression in the dermis during wound healing. *Proc. Natl. Acad. Sci. U.S.A* 1992;89:6896–900.
- [42] Werner S, Smola H, Liao X, Longaker MT, Krieg T, Hofschneider PH, et al. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. *Science* 1994;266:819–22.
- [43] Peters K, Werner S, Liao X, Wert S, Whittsett J, Williams L. Targeted expression of a dominant negative FGF receptor blocks branching morphogenesis and epithelial differentiation of the mouse lung. *EMBO J* 1994;13:3296–301.
- [44] Guo L, Degenstein L, Fuchs E. Keratinocyte growth factor is required for hair development but not for wound healing. *Genes Dev* 1996;10:165–75.
- [45] Yamasaki M, Miyake A, Tagashira S, Itoh N. Structure and expression of the rat mRNA encoding a novel member of the fibroblast growth factor family. *J. Biol. Chem* 1996;271:15918–21.
- [46] Beer HD, Florence C, Dammeier J, McGuire L, Werner S, Duan DR. Mouse fibroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression. *Oncogene* 1997;15:2211–8. <http://dx.doi.org/10.1038/sj.onc.1201383>.
- [47] Ohuchi H, Shibusawa M, Nakagawa T, Ohata T, Yoshioka H, Hirai Y, et al. A chick wingless mutation causes abnormality in maintenance of Fgf8 expression in the wing apical ridge, resulting in loss of the dorsoventral boundary. *Mech. Dev* 1997;62:3–13. S092547739600634X (pii).
- [48] Bellusci S, Grindley J, Emoto H, Itoh N, Hogan BL. Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. *Development* 1997;124:4867–78.
- [49] Sekine K, Ohuchi H, Fujiwara M, Yamasaki M, Yoshizawa T, Sato T, et al. Fgf10 is essential for limb and lung formation. *Nat. Genet* 1999;21:138–41. <http://dx.doi.org/10.1038/5096>.
- [50] Ohuchi H, Hori Y, Yamasaki M, Harada H, Sekine K, Kato S, et al. FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development. *Biochem. Biophys. Res. Commun* 2000;277:643–9. <http://dx.doi.org/10.1006/bbrc.2000.3721>. S0006-291X(00)93721-5 (pii).
- [51] Danopoulos S, Parsa S, Al Alam D, Tabatabai R, Baptista S, Tiozzo C, et al. Transient inhibition of FGFR2b-ligands signaling leads to irreversible loss of cellular (-catenin organization and signaling in AER during mouse limb development. *PLoS ONE* 2013;8:e76248. <http://dx.doi.org/10.1371/journal.pone.0076248>.
- [52] Parsa S, Kuremoto K, Seidel K, Tabatabai R, Mackenzie B, Yamaza T, et al. Signaling by FGFR2b controls the regenerative capacity of adult mouse incisors. *Development* 2010;137:3743–52. <http://dx.doi.org/10.1242/dev.051672>, 137/22/3743 (pii).
- [53] Parsa S, Ramasamy SK, De Langhe S, Gupte VV, Haigh JJ, Medina D, et al. Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling. *Dev Biol* 2008;317:121–31. <http://dx.doi.org/10.1016/j.ydbio.2008.02.014>. S0012-1606(08)00110-3 (pii).
- [54] Tai CC, Curtis JL, Sala FG, Del Moral PM, Chokshi N, Kanard RJ, et al. Induction of fibroblast growth factor 10 (FGF10) in the ileal crypt epithelium after massive small bowel resection suggests a role for FGF10 in gut adaptation. *Dev. Dyn* 2009;238:294–301. <http://dx.doi.org/10.1002/dvdy.21667>.
- [55] El Agha E, Al Alam D, Carraro G, MacKenzie B, Goth K, De Langhe SP, et al. Characterization of a novel fibroblast growth factor 10 (Fgf10) knock-in mouse line to target mesenchymal progenitors during embryonic development. *PLoS ONE* 2012;7:e38452. <http://dx.doi.org/10.1371/journal.pone.0038452>.
- [56] El Agha E, Herold S, Al Alam D, Quantius J, MacKenzie B, Carraro G, et al. Fgf10-positive cells represent a progenitor cell population during lung development and postnatally. *Development* 2014;141:296–306. <http://dx.doi.org/10.1242/dev.099747>.
- [57] Haan N, Goodman T, Najdi-Samiei A, Stratford CM, Rice R, El Agha E, et al. Fgf10-expressing tanycytes add new neurons to the appetite/energy-balance regulating centers of the postnatal and adult hypothalamus. *J. Neurosci* 2013;33:6170–80. <http://dx.doi.org/10.1523/JNEUROSCI.2437-12.2013>.
- [58] Hajihosseini MK, De Langhe S, Lana-Elola E, Morrison H, Sparshott N, Kelly R, et al. Localization and fate of Fgf10-expressing cells in the adult mouse brain implicate Fgf10 in control of neurogenesis. *Mol. Cell Neurosci* 2008;37:857–68. <http://dx.doi.org/10.1016/j.mcn.2008.01.008>. S1044-7431(08)00022-5 (pii).
- [59] Van Vliet P, Goumans M-J, Doevevans PA, Sluijter JPC. Human cardiomyocyte progenitor cells: a short history of nearly everything. *J. Cell Mol. Med* 2012;16:1669–73. <http://dx.doi.org/10.1111/j.1582-4934.2012.01535.x>.
- [60] Hotta Y, Sasaki S, Konishi M, Kinoshita H, Kuwahara K, Nakao K, et al. Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. *Dev. Dyn* 2008;237:2947–54. <http://dx.doi.org/10.1002/dvdy.21726>.
- [61] Lavine KJ, Yu K, White AC, Zhang X, Smith C, Partanen J, et al. Endocardial, Epicardial Derived FGF. Signals Regulate Myocardial Proliferation and Differentiation In Vivo. *Dev. Cell* 2005;8:85–95. <http://dx.doi.org/10.1016/j.devcel.2004.12.002>.
- [62] Kelly RG, Brown NA, Buckingham ME. The arterial pole of the mouse heart forms from Fgf10-expressing cells in pharyngeal mesoderm. *Dev. Cell* 2001;1:435–40. S1534-5807(01)00040-5 (pii).
- [63] Vega-Hernández M, Kovacs A, De Langhe S, Ornitz DM. FGF10/FGFR2b signaling is essential for cardiac fibroblast development and growth of the myocardium. *Development* 2011;138:3331–40. <http://dx.doi.org/10.1242/dev.064410>.
- [64] Marguerie A, Bajolle F, Zaffran S, Brown Na, Dickson C, Buckingham ME, et al. Congenital heart defects in Fgfr2-IIIb and Fgf10 mutant mice. *Cardiovasc. Res* 2006;71:50–60. <http://dx.doi.org/10.1016/j.cardiores.2006.03.021>.
- [65] Rochais F, Sturny R, Chao C-M, Mesbah K, Bennett M, Mohun TJ, et al. FGF10 promotes regional foetal cardiomyocyte proliferation and adult cardiomyocyte cell-cycle re-entry. *Cardiovasc. Res* 2014;104:432–42. <http://dx.doi.org/10.1093/cvr/cvu232>.
- [66] N. Rubin, A. Darehzereshki, S. Bellusci, V. Kaartinen, C.L. Lien, FGF10 Signaling enhances epicardial cell expansion during neonatal mouse heart

- repair, *J. Cardiovasc. Dis. Diagn.* 1 (2013) 1–9, doi:10.4172/jcdd.1000101.
- [67] Engel FB, Hsieh PCH, Lee RT, Keating MT. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. *Proc. Natl. Acad. Sci. U.S.A.* 2006;103:15546–51, <http://dx.doi.org/10.1073/pnas.0607382103>.
- [68] Meighan-Mantha RL, Hsu DKW, Guo Y, Brown SAN, Feng S-LY, Peifley KA, et al. The Mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. *J. Biol. Chem.* 1999;274:33166–76, <http://dx.doi.org/10.1074/jbc.274.46.33166>.
- [69] Novoyatleva T, Sajjad A, Pogoryelov D, Patra C, Schermuly RT, Engel FB. FGF1-mediated cardiomyocyte cell cycle reentry depends on the interaction of FGFR-1 and Fn14. *FASEB J* 2014;28:2492–503, <http://dx.doi.org/10.1096/fj.13-243576>.
- [70] Rosenblatt-velin N, Lepore MG, Cartoni C, Beermann F. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. *J. Clin. Invest* 2005;115:1724–33, <http://dx.doi.org/10.1172/JCI23418DS1>.
- [71] Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. *Mol. Endocrinol* 2010;24:2050–64, <http://dx.doi.org/10.1210/me.2010-0142>.
- [72] Barrios R, Pardo A, Ramos C, Montañó M, Ramirez R, Selman M. Upregulation of acidic fibroblast growth factor during development of experimental lung fibrosis. *Am. J. Physiol* 1997;273:L451–8.
- [73] Ramos C, Montañó M, Becerril C, Cisneros-Lira J, Barrera L, Ruíz V, et al. Acidic fibroblast growth factor decreases alpha-smooth muscle actin expression and induces apoptosis in human normal lung fibroblasts. *Am. J. Physiol. Lung Cell Mol. Physiol* 2006;291:L871–9, <http://dx.doi.org/10.1152/ajplung.00019.2006>.
- [74] Ramos C, Becerril C. FGF-1 reverts epithelial-mesenchymal transition induced by TGF-β1 through MAPK/ERK kinase pathway. *Am. J. Physiol. Lung Cell Mol. Physiol* 2010;229:222–31, <http://dx.doi.org/10.1152/ajplung.00070.2010>.
- [75] L. Xiao, Y. Du, Y. Shen, Y. He, H. Zhao, Z. Li, TGF-beta 1 induced fibroblast proliferation is mediated by the FGF-2/ERK pathway. *Front. Biosci.* (Landmark Ed.) 17 (2012) 2667–2674.
- [76] Ju W, Zhihong Y, Zhiyou Z, Qin H, Dingding W, Li S, et al. Inhibition of α-SMA by the ectodomain of FGFR2c attenuates lung fibrosis. *Mol. Med* 2012;18:992–1002, <http://dx.doi.org/10.2119/molmed.2011.00425>.
- [77] Guzy RD, Stoilov I, Elton TJ, Mecham RP, Ornitz DM. Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin. *Am. J. Respir Cell Mol. Biol* 2015;52:116–28, <http://dx.doi.org/10.1165/rcmb.2014-01840C>.
- [78] Leslie CC, McCormick-Shannon K, Mason RJ. Heparin-binding growth factors stimulate DNA synthesis in rat alveolar type II cells. *Am. J. Respir Cell Mol. Biol* 1990;2:99–106, <http://dx.doi.org/10.1165/ajrcmb.2.1.99>.
- [79] Li P, Oparil S, Sun J-Z, Thompson JA, Chen Y-F. Fibroblast growth factor mediates hypoxia-induced endothelin-1 receptor expression in lung artery smooth muscle cells. *J. Appl. Physiol* 2003;95:643–51, <http://dx.doi.org/10.1152/japplphysiol.00652.2002> (discussion 863).
- [80] Benisty JI, McLaughlin VV, Landzberg MJ, Rich JD, Newburger JW, Rich S, et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. *Chest* 2004;126:1255–61, <http://dx.doi.org/10.1378/chest.126.4.1255>.
- [81] Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. *J. Clin. Invest* 2009;119:512–23, <http://dx.doi.org/10.1172/JCI35070>.
- [82] Tu L, Dewachter L, Gore B, Fadel E, Darteville P, Simonneau G, et al. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. *Am. J. Respir Cell Mol. Biol* 2011;45:311–22, <http://dx.doi.org/10.1165/rcmb.2010-03170C>.
- [83] Ricard N, Tu L, Le Hires M, Huertas A, Phan C, Thuillet R, et al. Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension. *Circulation* 2014;129:1586–97, <http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007469>.
- [84] Kim J, Kang Y, Kojima Y, Lightbourne JK, Hu X, Aldred MA, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. *Nat. Med* 2013;19:74–82, <http://dx.doi.org/10.1038/nm.3040>.
- [85] Frank L. Protective effect of keratinocyte growth factor against lung abnormalities associated with hyperoxia in prematurely born rats. *Biol. Neonate* 2003;83:263–72, <http://dx.doi.org/10.1159/000069480>.
- [86] Plantier L, Marchand-Adam S, Antico VG, Boyer L, De Coster C, Marchal J, et al. Keratinocyte growth factor protects against elastase-induced pulmonary emphysema in mice. *Am. J. Physiol. Lung Cell Mol. Physiol* 2007;293:L1230–9, <http://dx.doi.org/10.1152/ajplung.00460.2006>.
- [87] Yildirim AO, Muyal V, John G, Müller B, Seifart C, Kasper M, et al. Palifermin induces alveolar maintenance programs in emphysematous mice. *Am. J. Respir. Crit. Care Med* 2010;181:705–17, <http://dx.doi.org/10.1164/rccm.200804-5730C>.
- [88] Benjamin JT, Smith RJ, Halloran BA, Day TJ, Kelly DR, Prince LS. FGF-10 is decreased in bronchopulmonary dysplasia and suppressed by Toll-like receptor activation. *Am. J. Physiol. Lung Cell Mol. Physiol* 2007;292:L550–8, <http://dx.doi.org/10.1152/ajplung.00329.2006>.
- [89] Gupte VV, Ramasamy SK, Reddy R, Lee J, Weinreb PH, Violette SM, et al. Overexpression of fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in mice. *Am. J. Respir. Crit. Care Med* 2009;180:424–36, <http://dx.doi.org/10.1164/rccm.200811-17940C> (pii).
- [90] Klar J, Blomstrand P, Brunmark C, Badhai J, Hakansson HF, Brange CS, et al. Fibroblast growth factor 10 haploinsufficiency causes chronic obstructive pulmonary disease. *J. Med. Genet* 2011;48:705–9, <http://dx.doi.org/10.1136/jmedgenet-2011-100166> (pii).
- [91] Volckaert T, Dill E, Campbell A, Tiozzo C, Majka S, Bellusci S, et al. Parabrachial smooth muscle constitutes an invasive epithelial stem cell niche in the mouse lung after injury. *J. Clin. Invest* 2011;121:4409–19, <http://dx.doi.org/10.1172/JCI58097>, 58097 (pii).
- [92] McQualter JL, Brouard N, Williams B, Baird BN, Sims-Lucas S, Yuen K, et al. Endogenous fibroblastic progenitor cells in the adult mouse lung are highly enriched in the sca-1 positive cell fraction. *Stem Cells* 2009;27:623–33, <http://dx.doi.org/10.1634/stemcells.2008-0866>.
- [93] McQualter JL, Yuen K, Williams B, Bertoncello I. Evidence of an epithelial stem/progenitor cell hierarchy in the adult mouse lung. *Proc. Natl. Acad. Sci. U.S.A.* 2010;107:1414–9, <http://dx.doi.org/10.1073/pnas.0909207107>.
- [94] McQualter JL, McCarty RC, Van der Velden J, O'Donoghue RJJ, Asselin-Labat M-L, Bozinovski S, et al. TGF-β signaling in stromal cells acts upstream of FGF-10 to regulate epithelial stem cell growth in the adult lung. *Stem Cell Res* 2013;11:1222–33, <http://dx.doi.org/10.1016/j.scr.2013.08.007>.
- [95] Hellerbrand C. Hepatic stellate cells—the pericytes in the liver. *Pflügers Arch* 2013;465:775–8, <http://dx.doi.org/10.1007/s00424-012-1209-5>.
- [96] Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. *Proc. Natl. Acad. Sci. U.S.A.* 1985;82:8681–5.
- [97] G. Carpino, A. Franchitto, S. Morini, S.G. Corradini, M. Merli, E. Gaudio, Activated hepatic stellate cells in liver cirrhosis. A morphologic and morphometrical study. *Ital. J. Anat. Embryol.* 109 (2004) 225–238.
- [98] Steiling H, Mühlbauer M, Bataille F, Schölermerich J, Werner S, Hellerbrand C. Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease. *Am. J. Pathol* 2004;165:1233–41, [http://dx.doi.org/10.1016/S0002-9440\(10\)63383-4](http://dx.doi.org/10.1016/S0002-9440(10)63383-4).
- [99] Steiling H, Wüstefeld T, Bugnon P, Brauchle M, Fässler R, Teupser D, et al. Fibroblast growth factor receptor signalling is crucial for liver homeostasis and regeneration. *Oncogene* 2003;22:4380–8, <http://dx.doi.org/10.1038/sj.onc.1206499>.
- [100] Tsai S-M, Wang W-P. Expression and function of fibroblast growth factor (FGF) 7 during liver regeneration. *Cell Physiol. Biochem* 2011;27:641–52, <http://dx.doi.org/10.1159/000330073>.
- [101] Takase HM, Itoh T, Ino S, Wang T, Koji T, Akira S, et al. FGF7 is a functional niche signal required for stimulation of adult liver progenitor cells that support liver regeneration. *Genes Dev* 2013;27:169–81, <http://dx.doi.org/10.1101/gad.204776.112>.
- [102] Berg T, Rountree CB, Lee L, Estrada J, Sala FG, Choe A, et al. Fibroblast growth factor 10 is critical for liver growth during embryogenesis and controls hepatoblast survival via beta-catenin activation. *Hepatology* 2007;46:1187–97, <http://dx.doi.org/10.1002/hep.21814>.
- [103] Antoine M, Wirz W, Tag CG, Gressner AM, Marvituna M, Wycislo M, et al. Expression and function of fibroblast growth factor (FGF) 9 in hepatic stellate cells and its role in toxic liver injury. *Biochem. Biophys. Res. Commun* 2007;361:335–41, <http://dx.doi.org/10.1016/j.bbrc.2007.06.189>.
- [104] Schaap FG, Leclercq IA, Jansen PLM, Olde Damink SW. Prometheus' little helper, a novel role for fibroblast growth factor 15 in compensatory liver growth. *J. Hepatol* 2013;59:1121–3, <http://dx.doi.org/10.1016/j.jhep.2013.07.013>.
- [105] Kong B, Huang J, Zhu Y, Li G, Williams J, Shen S, et al. Fibroblast growth factor 15 deficiency impairs liver regeneration in mice. *Am. J. Physiol. Gastrointest. Liver Physiol* 2014;306:G893–902, <http://dx.doi.org/10.1152/ajpgi.00337.2013>.
- [106] Padrisa-Altés S, Bachofner M, Bogorad RL, Pohlmeier L, Rossolini T, Böhm F, et al. Control of hepatocyte proliferation and survival by Fgf receptors is essential for liver regeneration in mice. *Gut* 2014, <http://dx.doi.org/10.1136/gutjnl-2014-307874>.
- [107] Le Moigne A, Martelly I, Barlovatz-Meimon G, Franquinet R, Aamiri A, Frisdal E, et al. Characterization of myogenesis from adult satellite cells cultured in vitro. *Int. J. Dev. Biol* 1990;34:171–80.
- [108] Allen RE, Dodson MV, Luiten LS. Regulation of skeletal muscle satellite cell proliferation by bovine pituitary fibroblast growth factor. *Exp. Cell Res* 1984;152:154–60, [http://dx.doi.org/10.1016/0014-4827\(84\)90239-8](http://dx.doi.org/10.1016/0014-4827(84)90239-8).
- [109] Yablonka-Reuveni Z, Rivera AJ. Temporal expression of regulatory and structural muscle proteins during myogenesis of satellite cells on isolated

- adult rat fibers. *Dev. Biol* 1994;164:588–603, <http://dx.doi.org/10.1006/dbio.1994.1226>.
- [110] Oliver L, Raulais D, Vigny M. Acidic fibroblast growth factor (aFGF) in developing normal and dystrophic (mdx) mouse muscles. Distribution in degenerating and regenerating mdx myofibres. *Growth Factors* 1992;7:97–106.
- [111] Menetrey J, Kasemkijwattana C, Day CS, Bosch P, Vogt M, Fu FH, et al. Growth factors improve muscle healing in vivo. *J. Bone Joint Surg. Br* 2000;82:131–7.
- [112] Stratos I, Madry H, Rotter R, Weimer A, Graff J, Cucchiariini M, et al. Fibroblast growth factor-2-overexpressing myoblasts encapsulated in alginate spheres increase proliferation, reduce apoptosis, induce adipogenesis, and enhance regeneration following skeletal muscle injury in rats. *Tissue Eng. Part. A* 2011;17:2867–77, <http://dx.doi.org/10.1089/ten.tea.2011.0239>.
- [113] Chakkalakal JV, Jones KM, Basson MA, Brack AS. The aged niche disrupts muscle stem cell quiescence. *Nature* 2012;490:355–60, <http://dx.doi.org/10.1038/nature11438>.
- [114] Floss T, Arnold HH, Braun T. A role for FGF-6 in skeletal muscle regeneration. *Genes Dev* 1997;11:2040–51.
- [115] Doukas J, Blease K, Craig D, Ma C, Chandler IA, Sosnowski BA, et al. Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle. *Mol. Ther* 2002;5:517–27, <http://dx.doi.org/10.1006/mthe.2002.0579>.
- [116] Armand A-S, Launay T, Pariset C, Della Gaspera B, Charbonnier F, Chanoine C. Injection of FGF6 accelerates regeneration of the soleus muscle in adult mice. *Biochim. Biophys. Acta* 2003;1642:97–105.
- [117] Sakaue H, Konishi M, Ogawa W, Asaki T, Mori T, Yamasaki M, et al. Requirement of fibroblast growth factor 10 in development of white adipose tissue. *Genes Dev* 2002;16:908–12, <http://dx.doi.org/10.1101/gad.983202>.
- [118] Asaki T, Konishi M, Miyake A, Kato S, Tomizawa M, Itoh N. Roles of fibroblast growth factor 10 (Fgf10) in adipogenesis in vivo. *Mol. Cell Endocrinol* 2004;218:119–28, <http://dx.doi.org/10.1016/j.mce.2003.12.017>.
- [119] Konishi M, Asaki T, Koike N, Miwa H, Miyake A, Itoh N. Role of Fgf10 in cell proliferation in white adipose tissue. *Mol. Cell Endocrinol* 2006;249:71–7, <http://dx.doi.org/10.1016/j.mce.2006.01.010>.
- [120] Ohta H, Itoh N. Roles of FGFs as adipokines in adipose tissue development, remodeling, and metabolism. *Front. Endocrinol. (Lausanne)* 2014;5:18, <http://dx.doi.org/10.3389/fendo.2014.00018>.
- [121] Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. *Biochim. Biophys. Acta* 2000;1492:203–6.
- [122] Kharitonov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. *J. Clin. Invest* 2005;115:1627–35, <http://dx.doi.org/10.1172/JCI23606>.
- [123] Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M, et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. *Mol. Endocrinol* 2008;22:1006–14, <http://dx.doi.org/10.1210/me.2007-0313>.
- [124] Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, et al. Fibroblast growth factor-21 regulates PPAR γ activity and the antidiabetic actions of thiazolidinediones. *Cell* 2012;148:556–67, <http://dx.doi.org/10.1016/j.cell.2011.11.062>.
- [125] Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, Flier JS, et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. *Endocrinology* 2011;152:2996–3004, <http://dx.doi.org/10.1210/en.2011-0281>.
- [126] Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, et al. A PPAR-(FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. *Nature* 2012;485:391–4, <http://dx.doi.org/10.1038/nature10998>.
- [127] Konishi M, Mikami T, Yamasaki M, Miyake A, Itoh N. Fibroblast growth factor-16 is a growth factor for embryonic brown adipocytes. *J. Biol. Chem* 2000;275:12119–22.
- [128] Robson MC, Phillips LG, Lawrence WT, Bishop JB, Youngerman JS, Hayward PG, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. *Ann. Surg* 1992;216:401–6 (discussion 406–408).
- [129] Richard JL, Parer-Richard C, Dures JP, Clouet S, Vannereau D, Bringer J, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. *Diabetes Care* 1995;18:64–9.
- [130] Hull MA, Knifton A, Filipowicz B, Brough JL, Vautier G, Hawkey CJ. Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration. *Gut* 1997;40:204–10.
- [131] Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. *Ann. Thorac. Surg* 1998;65:1540–4.
- [132] Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. *Circulation* 2000;102:1605–10.
- [133] Fu X, Shen Z, Chen Y, Xie J, Guo Z, Zhang M, et al. Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. *Lancet* 1998;352:1661–4, [http://dx.doi.org/10.1016/S0140-6736\(98\)01260-4](http://dx.doi.org/10.1016/S0140-6736(98)01260-4).
- [134] Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. *Lancet* 2002;359:2053–8.
- [135] Zhang Z, Liu Y, Dou Y, Sun G, Huang Q, Guo X. The therapeutic effects of basic fibroblast growth factor injected into tympanic cavity on sensorineural deafness. *Lin Chuang Er Bi Yan Hou Ke Za Zhi* 2002;16:603–4.
- [136] Mu J, Zhang X, Cheng J, Yuan Y. Effects of bFGF on the nasal mucosa after endoscopic sinus surgery. *Lin Chuang Er Bi Yan Hou Ke Za Zhi* 2005;19:646–7.
- [137] Kawaguchi H, Jingushi S, Izumi T, Fukunaga M, Matsushita T, Nakamura T, et al. Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose-escalation prospective trial on patients with osteotomy. *J. Orthop. Res* 2007;25:480–7, <http://dx.doi.org/10.1002/jor.20315>.
- [138] Han Y, Liu J. Autologous free fat particle grafting combined with bFGF to repair facial depression. *Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi* 2008;22:339–42.
- [139] Yao C, Yao P, Wu H, Zha Z. Acceleration of wound healing in traumatic ulcers by absorbable collagen sponge containing recombinant basic fibroblast growth factor. *Biomed. Mater* 2006;1:33–7, <http://dx.doi.org/10.1088/1748-6041/1/1/005>.
- [140] Kitamura M, Nakashima K, Kowashi Y, Fujii T, Shimauchi H, Sasano T, et al. Periodontal tissue regeneration using fibroblast growth factor-2: randomized controlled phase II clinical trial. *PLoS ONE* 2008;3:e2611, <http://dx.doi.org/10.1371/journal.pone.0002611>.
- [141] Hirano S, Kishimoto Y, Suehiro A, Kanemaru S, Ito J. Regeneration of aged vocal fold: first human case treated with fibroblast growth factor. *Laryngoscope* 2008;118:2254–9, <http://dx.doi.org/10.1097/MLG.0b013e3181845720>.
- [142] Takehara N, Tsutsumi Y, Tateishi K, Ogata T, Tanaka H, Ueyama T, et al. Controlled delivery of basic fibroblast growth factor promotes human cardiomyocyte-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. *J. Am. Coll. Cardiol* 2008;52:1858–65, <http://dx.doi.org/10.1016/j.jacc.2008.06.052>.
- [143] Kawaguchi H, Oka H, Jingushi S, Izumi T, Fukunaga M, Sato K, et al. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: a randomized, placebo-controlled trial. *J. Bone Miner. Res* 2010;25:2735–43, <http://dx.doi.org/10.1002/jbmr.146>.
- [144] Akita S, Akino K, Yakabe A, Tanaka K, Anraku K, Yano H, et al. Basic fibroblast growth factor is beneficial for postoperative color uniformity in split-thickness skin grafting. *Wound Repair Regen* 2010;18:560–6, <http://dx.doi.org/10.1111/j.1524-475X.2010.00620.x>.
- [145] Huang Y-F, Wang L-Q, DU G-P, Zhang Y-H, Ge M. The effect of recombinant bovine basic fibroblast growth factor on the LASIK-induced neurotrophic epitheliopathy and the recovery of corneal sensation after LASIK. *Zhonghua Yan Ke Za Zhi* 2011;47:22–6.
- [146] Takagi G, Miyamoto M, Tara S, Takagi I, Takano H, Yasutake M, et al. Controlled-release basic fibroblast growth factor for peripheral artery disease: comparison with autologous bone marrow-derived stem cell transfer. *Tissue Eng. Part A* 2011;17:2787–94, <http://dx.doi.org/10.1089/ten.tea.2010.0525>.
- [147] Kanemaru S-I, Umeda H, Kitani Y, Nakamura T, Hirano S, Ito J. Regenerative treatment for tympanic membrane perforation. *Otol. Neurotol* 2011;32:1218–23, <http://dx.doi.org/10.1097/MAO.0b013e31822e0e53>.
- [148] Meduri A, Aragona P, Grenga PL, Roszkowska AM. Effect of basic fibroblast growth factor on corneal epithelial healing after photorefractive keratectomy. *J. Refract. Surg* 2012;28:220–3, <http://dx.doi.org/10.3928/1081597X-20120103-02>.
- [149] Jiang X-W, Zhang Y, Zhang H, Lu K, Yang S-K, Sun G-L. Double-blind, randomized, controlled clinical trial of the effects of diosmetite and basic fibroblast growth factor paste on the treatment of minor recurrent aphthous stomatitis. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol* 2013;116:570–5, <http://dx.doi.org/10.1016/j.oooo.2013.07.003>.
- [150] Wu J-C, Huang W-C, Tsai Y-A, Chen Y-C, Cheng H. Nerve repair using acidic fibroblast growth factor in human cervical spinal cord injury: a preliminary Phase I clinical study. *J. Neurosurg. Spine* 2008;8:208–14, <http://dx.doi.org/10.3171/SPI/2008/8/3/208>.
- [151] Tsai P-Y, Cheng H, Huang W-C, Huang M-C, Chiu F-Y, Chang Y-C, et al. Outcomes of common peroneal nerve lesions after surgical repair with acidic fibroblast growth factor. *J. Trauma* 2009;66:1379–84, <http://dx.doi.org/10.1097/JTA.0b013e3181847a63>.
- [152] Nikol S, Baumgartner I, Van Belle E, Diehm C, Visoná A, Capogrossi MC, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. *Mol. Ther* 2008;16:972–8, <http://dx.doi.org/10.1038/mt.2008.33>.
- [153] Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised

- placebo-controlled trial of gene therapy in critical limb ischaemia. *Lancet* 2011;377:1929–37, [http://dx.doi.org/10.1016/S0140-6736\(11\)60394-2](http://dx.doi.org/10.1016/S0140-6736(11)60394-2).
- [154] Kaski JC, Consuegra-Sanchez L. Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. *Expert Opin. Biol. Ther* 2013;13:1749–53, <http://dx.doi.org/10.1517/14712598.2013.827656>.
- [155] Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. *N. Engl. J. Med* 2004;351:2590–8, <http://dx.doi.org/10.1056/NEJMoa040125>.
- [156] Wheeler G, Repifermin. *Human Genome Sciences/GlaxoSmithKline. IDrugs* 2001;4:813–9.
- [157] Robson MC, Phillips TJ, Falanga V, Odenheimer DJ, Parish LC, Jensen JL, et al. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. *Wound Repair Regen* 2001;9:347–52.
- [158] Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. *Aliment Pharmacol. Ther* 2003;17:1355–64.
- [159] Derrick T, Grillo AO, Vitharana SN, Jones L, Rexroad J, Shah A, et al. Effect of polyanions on the structure and stability of repifermin (keratinocyte growth factor-2). *J. Pharm. Sci* 2007;96:761–76, <http://dx.doi.org/10.1002/jps.20797>.
- [160] Huang M, Berkland C. Controlled release of repifermin from polyelectrolyte complexes stimulates endothelial cell proliferation. *J. Pharm. Sci* 2009;98:268–80, <http://dx.doi.org/10.1002/jps.21412>.
- [161] Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. *Biochem. J* 2011;437:199–213, <http://dx.doi.org/10.1042/BJ20101603>.
- [162] Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. *Med. Res. Rev* 2014;34:280–300, <http://dx.doi.org/10.1002/med.21288>.